Merck (MRK) Reports Positive Top-Line Results from Pivotal Phase 3 Trials Evaluating Combination of Doravirine/Islatravir for the Treatment of People with HIV-1 Infection
Go back to Merck (MRK) Reports Positive Top-Line Results from Pivotal Phase 3 Trials Evaluating Combination of Doravirine/Islatravir for the Treatment of People with HIV-1 Infection| Merck & Co. (NYSE: MRK) | Delayed: 119.05 -1.71 (1.42%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $120.76 | 52 Week High | $65.46 | |||
| Open | $121.50 | 52 Week Low | $47.97 | |||
| Day High | $121.90 | P/E | 80.99 | |||
| Day Low | $118.83 | EPS | $1.47 | |||
| Volume | 10,927,028 | |||||
